INTRODUCTION {#s1}
============

Prostate glands are the largest accessory glands in male genital organs, with pivotal physiological functions. Benign prostatic hyperplasia (BPH) is the most common disease causing urination disorder in medium-elderly males, and its morbidity is increasing with age \[[@R1]--[@R2]\]. BPH usually occurs in people beyond the age of 40, and its incidence rate can reach 50% and 83% in people aged 60 and 80 years, respectively \[[@R3]--[@R4]\]. According to statistics, approximately half of the BPH patients will undergo moderate or severe lower urinary tract symptom (LUTS) \[[@R5]\] which gravely impacts their living quality. At present, a few factors correlated with BPH clinical progression have been identified, including age, serum prostate specific antigen (PSA), prostate volume, maximum flow rate, postvoid residual urine (PVRV) and international prostate symptom score (I-PSS) \[[@R6]--[@R7]\]. Along with the advancement of population aging, BPH has been becoming more prevalent and inducing a series of medical and social-economic problems.

Prostate specific antigen (PSA) is a glucoproteinase, and its active form is a serine protease composed by 237 residues \[[@R8]\]. 70% of PSA have chymotrypsin-like activity, and are closely related to male fertility \[[@R9]\]. In addition, PSA can hydrolyze insulin-like growth factor binding proteins for the release of active free insulin-like growth factors (IGF-Is) which are secreted by epithelial cells and can promote cell\'s growth through paracrine \[[@R10]\]. Since IGF-I receptors are distributed on the surfaces of both normal and malignant prostatic cells, it has been hypothesized that PSA possesses certain pathological effects on the growth of prostate cancer cells \[[@R11]\]. It has been confirmed that the expression of PSA is regulated by androgen \[[@R12]\], as well as by its coding gene. The gene *PSA* is located on the long arm of chromosome 19, and contains 5 exons, 4 introns and 3 promoters. Documents have demonstrated that the polymorphism-158G/A in this gene can potentially affect the transcriptional control of androgen over expression, and thus exert certain influences on PSA expression and prostate development \[[@R13]--[@R14]\].

Association researches have previously discussed the effect of *PSA* gene -158G/A polymorphism on BPH risk, but the findings remained contradictory. Consequently, present meta-analysis was carried out backed by all available studies to systematically clarify such relationship.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

As presented in Figure [1](#F1){ref-type="fig"}, 95 studies were retrieved from databases after the initial search, and 73 of them were excluded after title and abstract review. Among the rest of 22 studies, 15 more were removed due to letter (*n* = 1), review (*n* = 1) and without controls (*n* = 13). Therefore, a total of 7 independent studies \[[@R15]--[@R21]\] were ultimately included in this meta-analysis, containing 758 cases and 752 controls. The principal characteristics of included studies are listed in Table [1](#T1){ref-type="table"}. Genotype distribution in controls was corresponded to HWE in all but one study \[[@R18]\].

![Flow diagram of selecting eligible studies for the meta-analysis](oncotarget-08-33953-g001){#F1}

###### Principal characteristics of the studies included in the meta-analysis

  First author-Year   Country   Ethnicity   Control source     Genotyping method   Case   Control   HWE                   
  ------------------- --------- ----------- ------------------ ------------------- ------ --------- ----- ----- ---- ---- -------
  Alptekin-2012       Turkey    Caucasian   Population-based   PCR-RFLP            2      6         3     1     9    1    0.035
  Ersekerci-2015      Turkey    Caucasian   Hospital-based     PCR-RFLP            8      13        7     7     13   10   0.495
  Gunes-2007          Turkey    Caucasian   Hospital-based     PCR-RFLP            34     62        40    15    44   43   0.499
  Sobti-2008          India     Asian       Hospital-based     PCR-RFLP            57     99        14    74    84   12   0.068
  Soni-2012           India     Asian       Population-based   PCR-RFLP            32     70        18    57    36   13   0.065
  Wang-2003           Japan     Asian       Hospital-based     PCR-RFLP            125    77        14    163   88   15   0.497
  Binnie-2005         UK        Caucasian   Population-based   PCR-RFLP            14     63        11    56    NA        

PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; HWE, Hardy-Weinberg equilibrium; NA, not available.

Meta-analysis results {#s2_2}
---------------------

The meta-analysis results in Table [2](#T2){ref-type="table"} demonstrated that *PSA* -158G/A polymorphism didn\'t affect the susceptibility of BPH significantly under all genetic models in total analysis. However, after subgroup analyses by ethnicity and source of control, *PSA* -158G/A polymorphism was correlated with decreased susceptibility of BPH in Caucasian group \[AA *vs*. GG: OR = 0.47, 95% CI = 0.25-0.89 (Figure [2](#F2){ref-type="fig"}); allele A *vs*. allele G: OR = 0.68, 95% CI = 0.49-0.93\], and linked with increased risk in Asian \[AA *vs*. GG: OR = 1.63, 95% CI = 1.02-2.60 (Figure [2](#F2){ref-type="fig"}); allele A *vs*. allele G: OR = 1.37, 95% CI = 1.03-1.83\] and population-based \[AA *vs*. GG: OR = 2.39, 95% CI = 1.07-5.38; allele A *vs*. allele G: OR = 1.83, 95% CI = 1.26-2.65 (Figure [3](#F3){ref-type="fig"})\] groups.

###### *PSA*-158G/A polymorphism and the susceptibility to benign prostatic hyperplasia

  Genetic comparison   Group/Subgroup      OR (95%CI)   *P*^h^               
  -------------------- ------------------- ------------ -------------------- -------
  AA vs.GG             Ethnicity           Caucasian    0.47 (0.25, 0.89)    0.691
                                           Asian        1.63 (1.02, 2.60)    0.464
                       Source of control   Population   2.39 (1.07, 5.38)    0.775
                                           Hospital     0.84 (0.44, 1.63)    0.089
                                           Total        1.07 (0.57, 2.00)    0.040
  AA+GA vs. GG         Ethnicity           Caucasian    0.64 (0.40, 1.04)    0.784
                                           Asian        1.72 (0.99, 2.99)    0.011
                       Source of control   Population   1.45 (0.46, 4.55)    0.025
                                           Hospital     1.00 (0.64, 1.58)    0.059
                                           Total        1.16 (0.72, 1.86)    0.002
  AA vs. GG+GA         Ethnicity           Caucasian    0.64 (0.40, 1.03)    0.336
                                           Asian        1.20 (0.77, 1.88)    0.987
                       Source of control   Population   1.41 (0.68, 2.91)    0.405
                                           Hospital     0.80 (0.56, 1.15)    0.329
                                           Total        0.90 (0.65, 1.24)    0.314
  A vs. G              Ethnicity           Caucasian    0.68 (0.49, 0.93)    0.549
                                           Asian        1.37 (1.03, 1.83)    0.102
                       Source of control   Population   1.83 (1.26, 2.65)    0.463
                                           Hospital     0.94 (0.66, 1.34)    0.021
                                           Total        1.09 (0.77, 1.55)    0.002
  GA vs. GG            Ethnicity           Caucasian    0.65 (0.35, 1.20)    0.789
                                           Asian        1.76 (0.97, 3.18)    0.008
                       Source of control   Population   1.54 (0.17, 13.70)   0.086
                                           Hospital     1.11 (0.77, 1.58)    0.211
                                           Total        1.28 (0.76, 2.15)    0.005

OR, odds ratio; CI, confidence interval; *P*~h~*, P*-value of heterogeneity test.

![Forest plot of BPH susceptibility associated with PSA -158G/A polymorphism under AA\
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Heterogeneity analysis {#s2_3}
----------------------

In Q test, significant heterogeneity was detected in AA *vs*. GG model (*P* = 0.040), AA+GA *vs*. GG model (*P* = 0.002), allele A *vs*. allele G model (*P* = 0.002) and GA *vs*. GG model (*P* = 0.005). Thus, the random-effects model was selected to evaluate overall results in these four comparisons, while the fixed-effects model was used for the other model (*P* = 0.314). As for the significant heterogeneity, it was dramatically attenuated or completely removed after stratification analyses by ethnicity and control source. We therefore hypothesized that its plausible origins might include these two aspects.

Sensitivity analysis {#s2_4}
--------------------

We omitted individual studies one at a time and re-calculated overall estimates to detect the impact of each included study on pooled results. Since pooled ORs were not substantially altered, our results were statistically stable and credible.

Evaluation of publication bias {#s2_5}
------------------------------

Both Begg\'s funnel plot and Egger\'s test were utilized to assess the possibility of existing significant publication bias. All funnel plots displayed symmetrical shapes (Figure [4](#F4){ref-type="fig"}), and Egger\'s test also provided evidence for the symmetry (*P* = 0.150), indicating publication bias was negligible.

![Begg\'s funnel plot for publication bias under the model AA\
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DISSCUSSION {#s3}
===========

BPH is a chronic progression disease, involving multiple factors and bothering elderly men in general \[[@R22]--[@R23]\]. Multiple hypotheses have been put forward for the pathogenesis of BPH, involving effects of hormone and intratesticular non-androgen materials, apoptosis, mesenchyme-epithelium interaction and growth factors. Literature has shown that age and testosterone level could impact the incidence of BPH notably. In addition, different races and genetic backgrounds are also considered as relevant components to BPH development.

PSA, regulated by androgen, is produced by prostate cells, and is generally used as a prostate disease marker to predict the enlargement of prostate volume clinically. *PSA* gene is polymorphic, and among others, a polymorphism at position -158 (G/A) is one of the most frequently studied objects. In a Turkey population, Gunes et al. found an increasing effect of the GG genotype of *PSA* -158G/A polymorphism on BPH susceptibility, with an age-adjusted OR of 2.77 (95% CI = 1.277-6.012) \[[@R20]\]. On the contrary, Abha Soni et al. insisted that the genotypes AA and GA of this polymorphism were significantly related to elevated risk of BPH in their study involving 120 BPH cases and 105 controls in Indians \[[@R21]\]. Whereas, a study by Alptekin and colleagues detected no statistically significant difference in the frequencies of genotypes or alleles of *PSA* -158G/A polymorphism between controls and BPH cases in Turks, suggesting that the polymorphism might not have independent influence on the disease onset \[[@R18]\].

It is necessary to perform a meta-analysis so as to combine those conflicting findings on the relationship between *PSA* -158G/A polymorphism and BPH susceptibility for a more convincing conclusion in view of distinct discrepancies among those findings. In our study, *PSA* -158G/A polymorphism showed no significant impact on BPH incidence in total analysis, but we observed with great interest that this polymorphism exerted opposite effects in different subgroups after stratification analysis by ethnicity and source of control. Specifically, under the genetic comparisons of AA *vs*. GG and A *vs*. G, *PSA* -158G/A polymorphism reduced the disease risk in Caucasian group, and increased the risk in Asian and population-based groups. To verify the reliability of the overall estimates from the present meta-analysis, we also implemented a series of tests. In sensitivity analysis, no qualitative alteration in pooled ORs was observed after the omission of any one of included studies, confirming the robustness of final outcomes. Besides, both funnel plot and Egger\'s test offered evidences supporting the absence of significant publication bias among selected studies. Hence, our study results had certain powerful in themselves.

Nevertheless, several limitations still needed to be acknowledged. First of all, we only included the articles previously published through online database searching, so possibly relevant reports unpublished or in other sources might be missed. Secondly, only seven eligible studies were ultimately incorporated into the current meta-analysis, with a relatively small sample size, and this situation might affect the precision of our results. Thirdly, not all eligible provided data adjusted for potentially confounding factors, which might introduce some bias into the final results. Fourthly, effects of gene-environment and gene-gene interactions on BPH susceptibility were not considered in this paper owing to inadequate data. Finally, since meta-analysis is a secondary analysis, the overall estimates may be affected by the quality of included studies. Therefore, our findings should be interpreted prudently.

In short, this meta-analysis suggests that *PSA* -158G/A polymorphism may be a protecting factor against BPH in Caucasian populations, but it may enhance the disease risk in Asians. In view of the shortcomings mentioned above, well-designed studies with larger sample sizes are warranted to verify these findings in future.

MATERIALS AND METHODS {#s4}
=====================

Inclusion and exclusion criteria {#s4_1}
--------------------------------

Studies were included into this meta-analysis if they met the following criteria: (i) exploring the correlation of *PSA* gene -158G/A polymorphism with BPH susceptibility; (ii) case-control studies; (iii) sufficient data for computing crude odds ratios (ORs) with their 95% confidence intervals (95% CIs). Papers not satisfying any one of the above standards were excluded from the current study. In addition, removed publications also contained letters and reviews.

Search for eligible studies {#s4_2}
---------------------------

Relevant studies were searched from PubMed, EMBASE, Chinese National Knowledge Infrastructure (CNKI) and Web of Science databases. Combinations of the following terms were adopted: "prostate specific antigen" or "PSA" or "KLK3" or "-158G/A", "polymorphism" or "mutation" or "variant", and "benign prostatic hyperplasia" or "BPH" or "benign prostate hyperplasia". References cited in pertinent articles were also screened manually to search for additional relevant papers.

Data extraction {#s4_3}
---------------

Two reviewers abstracted the following information independently from included studies: first author\'s name, year of publication, original country, ethnicity, control source, genotyping method, numbers of cases and controls, genotype frequencies in case and control groups, and *P* values for Hardy-Weinberg equilibrium (HWE) in controls. All discrepancies over extracted data were resolved *via* discussion between the two reviewers. If not, the third reviewer would be consulted to reach a final determination.

Statistical analysis {#s4_4}
--------------------

All the statistical tests were conducted using the STATA (version 12.0; StataCorp, College Station, TX) software. The conformity of genotype distribution to HWE in controls was investigated through the goodness of fit chi-square test, and *P* \> 0.05 were regarded as fine compliance to the Law. Pooled ORs with 95% CIs were calculated to estimate the relationship between *PSA* -158G/A polymorphism and BPH susceptibility under five models: AA *vs*. GG, AA+GA *vs*. GG, AA *vs*. GG+GA, allele A *vs*. allele G and GA *vs*. GG. The significance of the pooled ORs was determined by Z-test. Subgroup analyses according to ethnicity and source of control were performed so as to further test such relationship. Heterogeneity among the included studies was checked by chi-square based Q-test, and *P* \> 0.05 in the test suggesting the absence of significant heterogeneity among studies determined that the pooled ORs were computed with fixed-effects model \[[@R24]\]. Otherwise, random-effects model was used (*P* \< 0.05) \[[@R25]\]. Sensitivity analysis was implemented to examine the influence of each single study on pooled results. Begg\'s funnel plots and Egger\'s test \[[@R26]\] were used to measure potential publication bias across eligible studies.
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